Abstract
The safety and efficacy of Resolute Onyx zotarolimus-eluting stents in high bleeding risk (HBR) patients with 1-month dual antiplatelet therapy (DAPT) was previously demonstrated. This subgroup analysis examines 2-year outcomes in ACS and non-ACS patients in the Onyx ONE Clear study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Society for Cardiovascular Angiography & Interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
